The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review
出版年份 2016 全文链接
标题
The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review
作者
关键词
-
出版物
CANCER INVESTIGATION
Volume 34, Issue 7, Pages 313-339
出版商
Informa UK Limited
发表日期
2016-08-04
DOI
10.1080/07357907.2016.1206117
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients
- (2017) S. E. Rivkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ovarian cancer treatment: The end of empiricism?
- (2015) Stephanie Lheureux et al. CANCER
- Emerging therapies: angiogenesis inhibitors for ovarian cancer
- (2015) Amanda L Jackson et al. EXPERT OPINION ON EMERGING DRUGS
- Why have ovarian cancer mortality rates declined? Part III. Prospects for the future
- (2015) Victoria Sopik et al. GYNECOLOGIC ONCOLOGY
- Why have ovarian cancer mortality rates declined? Part I. Incidence
- (2015) Victoria Sopik et al. GYNECOLOGIC ONCOLOGY
- A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia
- (2015) H. Hirte et al. GYNECOLOGIC ONCOLOGY
- Nintedanib: From Discovery to the Clinic
- (2015) Gerald J. Roth et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the microenvironment in ovarian cancer
- (2015) Stephanie Lheureux et al. LANCET ONCOLOGY
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
- (2015) Sandro Pignata et al. LANCET ONCOLOGY
- Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer
- (2015) Maria Luisa Gasparri et al. TUMOR BIOLOGY
- A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†
- (2014) I. A. McNeish et al. ANNALS OF ONCOLOGY
- Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904
- (2014) Robert L. Coleman et al. EUROPEAN JOURNAL OF CANCER
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- (2014) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy?
- (2014) V. L. Damaraju et al. MOLECULAR CANCER THERAPEUTICS
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Targeting tyrosine-kinases in ovarian cancer
- (2013) Matteo Morotti et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
- (2013) R.J. Schilder et al. GYNECOLOGIC ONCOLOGY
- A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma
- (2013) Thomas J. Herzog et al. GYNECOLOGIC ONCOLOGY
- Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma
- (2013) Koji Matsuo et al. GYNECOLOGIC ONCOLOGY
- Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- New perspectives in ovarian cancer treatment
- (2013) Bernd C. Schmid et al. MATURITAS
- A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
- (2012) K. H. Baumann et al. ANNALS OF ONCOLOGY
- New insights into ovarian cancer pathology
- (2012) J. Prat ANNALS OF ONCOLOGY
- The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer
- (2012) Ting Gui et al. Cancer Epidemiology
- Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin
- (2012) C. Jovelet et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Cediranib: a VEGF receptor tyrosine kinase inhibitor
- (2012) Marina Sahade et al. Future Oncology
- Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2012) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube
- (2012) Ignacio Romero Noguera et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
- (2012) Susana M. Campos et al. GYNECOLOGIC ONCOLOGY
- The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
- (2011) Q Sheng et al. BRITISH JOURNAL OF CANCER
- Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
- (2011) Samar Masoumi Moghaddam et al. CANCER AND METASTASIS REVIEWS
- Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
- (2011) Lubomir Bodnar et al. GYNECOLOGIC ONCOLOGY
- Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
- (2011) R. Ramasubbaiah et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
- (2011) S. John Weroha et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
- (2011) Agustin A. Garcia et al. GYNECOLOGIC ONCOLOGY
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Status of Src Inhibitors in Solid Tumor Malignancies
- (2011) L. N. Puls et al. ONCOLOGIST
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) N. Colombo et al. ANNALS OF ONCOLOGY
- A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
- (2010) J. J. Biagi et al. ANNALS OF ONCOLOGY
- Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer
- (2010) Martin Pölcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer
- (2010) S. K. Chambers et al. CLINICAL CANCER RESEARCH
- Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
- (2010) Patricia Pautier et al. GYNECOLOGIC ONCOLOGY
- A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)
- (2010) H. Hirte et al. GYNECOLOGIC ONCOLOGY
- Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
- (2010) Stephanie V. Blank et al. GYNECOLOGIC ONCOLOGY
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer
- (2010) Stephen A. Welch et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
- (2010) Rebecca L Stone et al. LANCET ONCOLOGY
- Angiogenesis and ovarian cancer
- (2009) César Gómez-Raposo et al. Clinical & Translational Oncology
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse molecular pathways in ovarian cancer and their clinical significance
- (2009) Carmela Ricciardelli et al. MATURITAS
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis
- (2008) Daniela Matei et al. CANCER
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
- (2008) Russell J. Schilder et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started